Typically, macrophages perform phagocytosis, a process by which they engulf and digest dying or dead cells, aiding in tissue cleanup and repair. However, the Nagoya University team showed that when macrophages engulf dying cancer cells within tumors, they begin producing inflammatory signaling molecules called cytokines. These cytokines initiate a cascade of molecular events inside the surviving cancer cells, leading to sustained tumor growth and proliferation. This unexpected finding underscores the intricate ways cancer cells can hijack normal biological processes for their advantage.

The key molecular actors identified in this study are the JAK and STAT proteins, which play central roles in cell signaling pathways governing growth, immune responses, and tissue maintenance. Upon activation by macrophage-derived cytokines, JAK and STAT proteins stimulate surviving cancer cells to produce their own cytokine molecule called Upd3, an analog of human interleukin-6 (IL-6). Through this self-reinforcing feedback loop, cancer cells amplify growth-promoting signals, creating a microenvironment conducive to tumor expansion and resistance to conventional immune attacks.

Fruit flies offer a powerful model system for dissecting these interactions due to their conserved immune and genetic pathways with humans. The researchers generated minute tumors in the fly’s eye tissue and applied fluorescent markers to live-track the behavior of cancer cells and macrophages using high-resolution microscopy. By selectively switching genes on or off within the flies, the scientists were able to manipulate the macrophages’ phagocytic activity and cytokine production, precisely elucidating the chain of events that drive tumor growth.

One striking outcome of this investigation was the demonstration that interrupting any stage of this feedback loop—with either genetic modifications that hinder macrophage engulfment of dying cancer cells or by suppressing cytokine production—resulted in a significant reduction of tumor expansion. These findings carry profound implications for cancer therapy, particularly interventions that traditionally seek to enhance immune cell activity to eliminate tumors. Augmenting macrophage phagocytosis without understanding this feedback mechanism could potentially exacerbate tumor growth instead of impeding it.

Moreover, the study highlights the cunning adaptability of cancer cells, which are not mere recipients of external growth signals but active participants in amplifying their own survival and proliferation cues. By co-opting the JAK-STAT signaling pathway and producing Upd3 cytokines themselves, cancer cells create a self-sustaining loop that exaggerates inflammatory signals within the tumor microenvironment. This insight clarifies why certain aggressive cancers with high rates of cell death paradoxically continue to grow despite immune infiltration.

Senior researcher Professor Shizue Ohsawa emphasized the evolutionary conservation underpinning these phenomena, noting that the molecular pathways identified in fruit flies share significant similarities with those in humans. This conservation raises the possibility that similar macrophage-cancer cell interactions may underlie tumor progression in human cancers, especially in cases where cell death within tumors is prevalent. Understanding these mechanisms could unveil new therapeutic targets aimed at disrupting the pathological dialogue between macrophages and cancer cells.

From a broader perspective, this research may reshape strategies in immunotherapy, encouraging a more nuanced approach that considers not only the activation but also the behavioral consequences of immune cells within the tumor microenvironment. Blocking the deleterious aspects of macrophage phagocytosis or cytokine amplification may prove vital in tempering tumor-promoting inflammation. This approach diverges from the current paradigm of broadly boosting immune system activity and highlights the need for precision in mobilizing immune defenses against cancer.

The integration of advanced genetic tools, live-cell imaging, and molecular analyses enabled the researchers to unravel these complex dynamics with remarkable detail. The study’s elegant design also underscores the relevance of invertebrate models for uncovering fundamental principles of human disease. By illuminating the molecular crosstalk between dying cancer cells, immune phagocytes, and surviving tumor cells, the work opens avenues for the development of drugs that specifically target the cytokine feedback network to inhibit tumor growth.

Published in the journal Current Biology, this study not only challenges existing assumptions about immune cell roles in cancer but also encourages a reevaluation of therapeutic strategies that harness or modulate the immune system. The identification of Upd3 as a key cytokine in this process spotlights IL-6-related signaling pathways as promising candidates for targeted therapies in oncology. Future research may expand on these findings to explore the translational potential in human cancers.

This discovery also exemplifies the complex duality of immune responses within cancer: while immune cells can attack tumors, under certain conditions, they may inadvertently create a microenvironment that supports tumor survival and expansion. Therapeutically, this underscores the importance of discerning context-dependent immune cell functions to avoid unintended consequences in cancer treatment. As the field of immuno-oncology advances, the detailed molecular understanding provided by this research will inform the design of safer, more effective interventions.

In conclusion, the Nagoya University study revolutionizes our conception of macrophage function in cancer biology. The revelation that macrophage phagocytosis of dying cancer cells can induce a growth-promoting feedback loop mediated by cytokine signaling challenges the conventional wisdom guiding cancer immunotherapy. This novel insight lays critical groundwork for developing next-generation treatments that finely tune immune system activities to suppress rather than promote tumor growth, marking a significant stride toward conquering cancer.

Subject of Research: Animals

Article Title: Macrophages promote tumor growth by phagocytosis-mediated cytokine amplification in Drosophila

News Publication Date: 25-Jun-2025

Web References: http://dx.doi.org/10.1016/j.cub.2025.05.068

References: Hirooka et al., 2025, Current Biology, DOI: 10.1016/j.cub.2025.05.068

Image Credits: Eri Hirooka, Nagoya University

Keywords: Tumor microenvironments, Macrophages, Phagocytosis, Cytokines, Tumor growth, Cancer cells, Immune cells

CAR-T cell therapy—short for Chimeric Antigen Receptor T-cell therapy—revolutionized cancer treatment by genetically engineering patients’ own T cells to recognize and eliminate cancer cells. While these engineered cells have demonstrated unprecedented success in treating blood cancers like leukemia and lymphoma, solid tumors have remained recalcitrant due to their complex microenvironments and limited accessibility. Overcoming these barriers calls for refined and specialized CAR designs tailored to the unique biology of solid tumors.

The Nagoya team singled out Eva1, a less explored but compelling antigen, given its unusually high expression on lung, pancreatic, and liver tumor cells, alongside relatively sparse distribution on normal tissues. This antigen’s small molecular footprint augurs well for enhanced immune cell engagement. Eva1’s diminutive size enables CAR-T cells to form stronger and more effective immunological synapses—critical junctions where immune cells and their targets physically connect, facilitating superior signaling that boosts T-cell activation and antitumor functions.

Central to their breakthrough was the intricate engineering of the CAR construct itself, focusing on two pivotal aspects: the spacer region and the intracellular domains. The spacer dictates the spatial configuration between the CAR-T cell and the tumor cell during contact, influencing the strength and duration of cell-to-cell interactions. Meanwhile, intracellular signaling domains modulate the activation state, persistence, and cytotoxic potency of the CAR-T cells. By creating sixteen variant CARs featuring combinations of humanized Eva1-binding antibodies, tailored spacer lengths, and distinct intracellular co-stimulatory motifs, the researchers identified ideal configurations that maximized therapeutic impact.

Humanization of the antibody fragment was crucial for clinical translation. Originally derived from mouse antibodies against Eva1, the binding domains were restructured to closely mimic human antibodies, minimizing the risk of adverse immune rejection when administered to patients. This refined design specifically increased affinity and selectivity for Eva1, reducing off-target effects and ensuring that the CAR-T cells preferentially recognize malignant, high-Eva1-expressing tumor cells.

Among the configurations tested, those employing a short spacer combined with co-stimulatory intracellular domains 4-1BB or a dual CD79A/CD40 module stood out. These constructs conferred superior expansion, cytokine secretion, and cytotoxic capabilities upon CAR-T cells, culminating in highly effective elimination of tumors in murine models that mimic human lung and pancreatic cancers. Such preclinical success underscores a potential leap forward in tackling solid tumors, which have been notoriously refractory to existing immunotherapies.

Safety, a paramount concern in CAR-T therapy, was rigorously evaluated given that Eva1 is not completely tumor-specific and is also present in low amounts on normal monocytes, a subset of white blood cells. Encouragingly, the engineered CAR-T cells demonstrated exquisite sensitivity to antigen density, activating robustly only upon encountering cells with high Eva1 expression typical of cancer cells, while largely sparing normal monocytes. This on-target, off-tumor discrimination signifies a promising safety profile, essential to minimize collateral damage and treatment-related toxicities in future clinical applications.

The sophisticated immune synapse formation observed with Eva1CAR-T cells may hold the key to their enhanced efficacy. Due to Eva1’s molecular structure and size, the engineered T cells can establish more intimate and stable physical contacts with cancer cells, reinforcing sustained T-cell receptor signaling, cytokine production, and proliferative responses. These features collectively drive more potent and durable antitumor immunity, overcoming the limitations seen in earlier CAR-T designs targeting bulkier or less accessible antigens.

Dr. Seitaro Terakura, lead investigator from Nagoya University’s Graduate School of Medicine, emphasized the clinical significance of these findings. He noted that the strategy offers a tangible pathway for treating solid tumors that have thus far evaded effective immune-based therapies. Tumors of priority include lung, pancreatic, and liver cancers—malignancies responsible for significant global mortality, often diagnosed at advanced stages with poor prognosis under current therapeutic regimes.

The team is now poised to translate this promising preclinical research into human trials. Before this can occur, thorough safety assessments are underway using mouse models engineered to express mouse Eva1. Developing a murine Eva1-specific CAR-T allows detailed toxicity profiling, verifying that the therapy does not induce deleterious damage to normal tissue expressing basal levels of Eva1. Successful demonstration of safety will pave the way for pivotal clinical trials in patients, moving closer to the ultimate goal of offering a lifesaving intervention.

Looking forward, the researchers plan to collaborate with biotech and pharmaceutical partners to advance clinical development. The optimization framework established here—combining antigen selection, CAR spacer engineering, and intracellular co-stimulatory domain tuning—may also provide a blueprint for developing therapies against other challenging tumor antigens. This modular and rational design paradigm promises to expand the arsenal of effective, safe, and targeted CAR-T cell therapies for solid malignancies.

As this approach transitions from bench to bedside, it promises enormous implications not only for patient outcomes but also for the broader field of cancer immunotherapy. Harnessing the immune system’s power with precision-engineered cellular therapies signals a new dawn where even the most intractable cancers might be conquered with minimal toxicity and maximal clinical benefit.

The success of Eva1-targeting CAR-T cells embodies the fusion of cutting-edge molecular engineering, immunological insight, and translational ambition. It underscores how targeted molecular design can overcome biological hurdles previously thought insurmountable, offering hope for more effective treatments against the world’s deadliest cancers in the near future.

Subject of Research: Animals
Article Title: Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells
News Publication Date: 7-May-2025
Web References: Journal for ImmunoTherapy of Cancer, DOI: 10.1136/jitc-2024-009825
Image Credits: Keiko Itano, Nagoya University
Keywords: Cancer immunotherapy, Immune cells, Antibodies, Antigens, Immune response, Cancer cells, Cancer research, Liver cancer, Lung cancer, Pancreatic cancer, Adoptive T cell therapy

CAR-T therapy has garnered significant attention in the oncological community because of its tailor-made approach to treating cancer. By engineering a patient’s own T cells, clinicians can magnify their ability to seek and destroy malignant cells. However, the full therapeutic potential of CAR-T cells is often curtailed by challenges posed by tumor microenvironments. Cancerous cells can create hostile conditions, leading to T cell exhaustion and diminished anticancer responses over time. The current research addresses these shortcomings by proposing gene modifications that render CAR-T cells both more resilient and effective against tumors.

Researchers employed the CRISPR screening technique—a groundbreaking method that allows scientists to systematically disable individual genes within the cells—to spotlight candidates that might enhance CAR-T therapies. By “knocking out” various genes, the researchers explored which modifications could contribute to superior T cell performance. Their investigations highlighted the CUL5 gene as a critical factor; its downregulation resulted in an extended life span and sustained activity of CAR-T cells.

The role of CUL5 in cellular biology is significantly based on its involvement in the ubiquitin-proteasome system, a vital process where proteins are tagged for degradation. The findings suggest that when CUL5 is inhibited, signaling pathways that facilitate T cell growth, specifically the JAK-STAT pathway, are activated in a more sustained manner. This pathway is essential for various immune functions, including cell growth and differentiation. Therefore, less CUL5 activity can lead to enhanced proliferation and activity of CAR-T cells, potentially allowing these engineered immune cells to effectively continue fighting cancer for longer periods.

In preclinical studies involving mice with B-cell lymphoma, researchers demonstrated that CUL5-deficient CAR-T cells significantly outperformed their conventional counterpart. In these trials, tumors treated with the modified CAR-T cells not only shrank more effectively but also showed a reduced rate of relapse. This provides compelling evidence that manipulating the expression of specific genes, like CUL5, can dramatically improve the therapeutic window of CAR-T therapies and may extend their applicability to a broader array of cancers.

Although current practices for creating CUL5-deficient CAR-T cells involve electroporation, this technique carries risks of cellular damage and is impractical for large-scale clinical applications. The innovative approach adopted by the Nagoya University researchers circumvents this limitation. By leveraging viral vectors to deliver genetic material for CUL5 attenuation, the research team successfully demonstrated that CAR-T cells maintain their viability and functional capacity post-modification.

The implications of this research extend far beyond hematological cancers, potentially unlocking new strategies for tackling solid tumors—historically among the most challenging types to treat with CAR-T cell therapies. Researchers are now keen to investigate whether this gene-modification technique can be extrapolated to other oncological contexts, enabling more comprehensive cancer treatment modalities.

Through this study, the team not only elucidates the pivotal role of the CUL5 gene in the context of T cell functionality but also emphasizes the power of genetic engineering in oncology. Given the complexity of cancer biology and the plasticity of the tumor microenvironment, targeted gene interventions could become a cornerstone of future cancer therapies.

As the research team continues to explore this promising field, the prospect of harnessing gene editing and viral delivery mechanisms opens up a new frontier in personalized medicine. By optimizing CAR-T cell therapies through genetic modifications, clinicians may be able to offer improved outcomes for patients facing daunting diagnoses and enhance the overall efficacy of cancer immunotherapy options.

In light of these advances, further studies will undoubtedly seek to answer critical questions surrounding the safety and long-term effects of such engineered therapies. Bridging the gap between laboratory findings and clinical application remains a priority for researchers, as they aspire to develop novel, personalized approaches to cancer treatment that can be easily adopted in clinical settings.

This pivotal research may inspire a new wave of investigation into gene-based therapies, reflecting growing interest in the intersection of genetics and immunotherapy as a viable pathway toward enhanced cancer care. As scientists deepen their understanding of the molecular mechanics underlying immune cell activity, the timelines for bringing innovative treatments into the hands of oncologists may shorten considerably, invigorating hope for patients and families confronting significant medical challenges.

With these innovations, the future holds promise for a new era in cancer treatment—an era where engineered immune cells can be tailored not just to act against cancer but to thrive in its presence, turning the tide in the relentless battle against this pervasive illness.

Subject of Research: Gene-modified CAR-T cell therapy
Article Title: Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
News Publication Date: October 2023
Web References: DOI Link
References: Nature Communications
Image Credits: Reiko Matsushita

Keywords: Cancer, Gene Therapy, CAR-T Cells, CUL5, Immunotherapy, Hematologic Malignancies, CRISPR, JAK-STAT Pathway.